financetom
Business
financetom
/
Business
/
ServiceNow Q2 Results Expected to Beat Consensus on Core Offerings Strength, AI Initiatives, Truist Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ServiceNow Q2 Results Expected to Beat Consensus on Core Offerings Strength, AI Initiatives, Truist Says
Jul 23, 2025 12:13 PM

02:54 PM EDT, 07/23/2025 (MT Newswires) -- ServiceNow ( NOW ) Q2 results will beat consensus due to continued strength in its core offerings and artificial intelligence initiatives, but the company will give conservative guidance to manage macroeconomic uncertainty and a heavy Federal quarter ahead, Truist Securities said in a note on Wednesday.

The Pro Plus stock keeping unit and Agentic AI are showing early momentum, with management realizing uplift in upgrades and broadening use cases across products like IT Service Management Plus and Security Operations Plus, according to the note.

The firm said that ServiceNow's ( NOW ) decision to price Agentic AI features on a consumption basis could make adoption easier and increase monetization; however, it is too early to see this impact in 2025 guidance.

Truist expects Federal spending to remain a concern, but recent wins, including $1 million federal deal, show promise, and more deal flow in Q2 could lift full-year guidance.

The firm maintained its buy rating on ServiceNow's ( NOW ) stock with a $1,200 price target.

Price: 961.03, Change: -1.34, Percent Change: -0.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease
MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease
Nov 10, 2025
09:28 AM EST, 11/10/2025 (MT Newswires) -- MannKind ( MNKD ) said Monday it has discontinued its phase 3 trial evaluating MNKD-101, a nebulized clofazimine inhalation suspension, for the treatment of nontuberculous mycobacterial lung disease. The company said no sputum culture conversions were observed from the first 46 participants who completed the double-blind treatment phase and the Data Safety Monitoring...
Nevada King Said Extended Mineralization at Silver Park East
Nevada King Said Extended Mineralization at Silver Park East
Nov 10, 2025
09:21 AM EST, 11/10/2025 (MT Newswires) -- Nevada King Gold ( NKGFF ) announced Monday results for the remaining 10 holes at its Silver Park East target from the Phase III drill program, with a highlight being the extending of mineralization 150 metres along strike. Among Silver Park East highlights, NKG said drill results released today confirm gold and silver...
Form 8.3
Form 8.3
Nov 10, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Epiq Announces Strategic Realignment With Sale of Business Process Outsourcing Business
Epiq Announces Strategic Realignment With Sale of Business Process Outsourcing Business
Nov 10, 2025
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Epiq announced today the sale of its Global Business Transformation Solutions (Epiq GBTS) division to K2 Services, a leading managed services provider. Epiq is a technology and services leader, taking on large-scale and complex tasks for corporations, law firms, and the courts by integrating people, process, technology, and data intelligence to streamline...
Copyright 2023-2026 - www.financetom.com All Rights Reserved